ATE308365T1 - Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung - Google Patents

Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung

Info

Publication number
ATE308365T1
ATE308365T1 AT98918361T AT98918361T ATE308365T1 AT E308365 T1 ATE308365 T1 AT E308365T1 AT 98918361 T AT98918361 T AT 98918361T AT 98918361 T AT98918361 T AT 98918361T AT E308365 T1 ATE308365 T1 AT E308365T1
Authority
AT
Austria
Prior art keywords
taxans
compositions
oral administration
oral
administration
Prior art date
Application number
AT98918361T
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Application granted granted Critical
Publication of ATE308365T1 publication Critical patent/ATE308365T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98918361T 1997-05-27 1998-04-22 Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung ATE308365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
ATE308365T1 true ATE308365T1 (de) 2005-11-15

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918361T ATE308365T1 (de) 1997-05-27 1998-04-22 Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung

Country Status (22)

Country Link
EP (1) EP0994706B1 (de)
JP (1) JP2002500667A (de)
KR (1) KR100615783B1 (de)
CN (2) CN1261275A (de)
AR (1) AR012731A1 (de)
AT (1) ATE308365T1 (de)
AU (1) AU7130098A (de)
BR (1) BR9809694A (de)
CA (1) CA2290446C (de)
CZ (1) CZ9904244A3 (de)
DE (1) DE69832173T2 (de)
DK (1) DK0994706T3 (de)
ES (1) ES2247690T3 (de)
HU (1) HUP0003546A3 (de)
IL (2) IL132992A0 (de)
NO (1) NO995812L (de)
PL (1) PL337064A1 (de)
RU (1) RU2205005C2 (de)
SK (1) SK157599A3 (de)
UA (1) UA74767C2 (de)
WO (1) WO1998053811A1 (de)
ZA (1) ZA984268B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
JP2002505682A (ja) * 1997-06-20 2002-02-19 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド パクリタクセルの可溶性プロドラッグ
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE60030283T2 (de) 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
RU2236226C2 (ru) * 1999-06-18 2004-09-20 Бейкер Нортон Фармасьютикалз, Инк. Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
EP1623706A3 (de) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomische Dosierung von Taxane zur Hemmung des Krebswuchses
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2010141584A2 (en) * 2009-06-02 2010-12-09 Nikan Pharmaceuticals, Llc Antagonism of human formyl peptide receptor for treatment of disease
BR112023018826A2 (pt) * 2021-03-17 2024-03-12 Dompe Farm Spa Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
KR100220538B1 (ko) * 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE69507702T2 (de) * 1994-07-26 1999-08-26 Indena S.P.A. Semisynthetisch taxal derivate mit antitumor wirkung
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
AU3486297A (en) * 1996-06-17 1998-01-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999049848A1 (en) * 1998-04-01 1999-10-07 Rtp Pharma Inc. Anticancer compositions

Also Published As

Publication number Publication date
ZA984268B (en) 1999-06-23
UA74767C2 (en) 2006-02-15
IL132992A0 (en) 2001-03-19
DE69832173D1 (de) 2005-12-08
HK1026637A1 (en) 2000-12-22
PL337064A1 (en) 2000-07-31
CA2290446C (en) 2008-01-29
HUP0003546A3 (en) 2002-12-28
EP0994706A4 (de) 2001-05-16
DE69832173T2 (de) 2006-08-03
NO995812L (no) 2000-01-25
EP0994706A1 (de) 2000-04-26
JP2002500667A (ja) 2002-01-08
IL132992A (en) 2006-08-20
CN1550231A (zh) 2004-12-01
AR012731A1 (es) 2000-11-08
AU7130098A (en) 1998-12-30
WO1998053811A1 (en) 1998-12-03
HUP0003546A2 (hu) 2002-11-28
ES2247690T3 (es) 2006-03-01
KR20010013025A (ko) 2001-02-26
KR100615783B1 (ko) 2006-08-25
CA2290446A1 (en) 1998-12-03
CN1261275A (zh) 2000-07-26
NO995812D0 (no) 1999-11-26
DK0994706T3 (da) 2006-03-06
BR9809694A (pt) 2000-10-03
CZ9904244A3 (cs) 2001-10-17
EP0994706B1 (de) 2005-11-02
SK157599A3 (en) 2002-10-08
RU2205005C2 (ru) 2003-05-27

Similar Documents

Publication Publication Date Title
PT1039909E (pt) Metodo de producao e composicao de uma preparacao oral de itraconazole
ATE308365T1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
DE69903515D1 (de) Zusammensetzung zur herstellung von temporären zahnkronen und haltebrücken
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
DE69607321D1 (de) Reinigungsverfahren und zusammensetzung
FI973475L (fi) Koostumus ja sitä sisältävä tuote
ATE186447T1 (de) Zusammensetzung und verwendung
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
DE69729570D1 (de) Fotpempfindliche zusammensetzung und deren verwendung
DE59711379D1 (de) Oral applizierbare formulierungen von chinolon- oder naphthyridoncarbonsäuren
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69724629D1 (de) Zusammensetzungen und deren verwendungen
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
PL342500A1 (en) Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists
DE59708905D1 (de) Injektionsformulierungen von avermectinen und milbemycinen
DE69934889D1 (de) Herstellung und reinigung von diboranen
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
DE69522188D1 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
DE69525101D1 (de) Haftungsfördernde Zusammensetzungen und diese enthaltende härtbare Silikon-Zusammensetzungen
DE69819671D1 (de) Flüssige Reinigungszusammensetzungen und deren Verwendung
DE69803867D1 (de) Reinigende kosmetische zusammensetzung und verwendung
FI952297A7 (fi) Fluoridia vapauttava hammaspohjustekoostumus ja menetelmä sen käyttämiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0994706

Country of ref document: EP

REN Ceased due to non-payment of the annual fee